Research programme: T cell therapies - Phio Pharmaceuticals/Helmholtz Zentrum
Alternative Names: Adoptive T-cell therapies - Phio Pharmaceuticals/Helmholtz Zentrum; INTASYL™Latest Information Update: 28 Jun 2024
At a glance
- Originator Phio Pharmaceuticals
- Developer Helmholtz Zentrum Munchen; Phio Pharmaceuticals
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
- 29 May 2020 Pharmacodynamics data from a preclinical study in Cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
- 01 May 2020 Preclinical trials in Cancer in USA (Intratumoural), before May 2020